Cerevel Therapeutics

About:

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Website: https://www.cerevel.com

Twitter/X: CerevelTx

Top Investors: Pfizer, RA Capital Management, Fidelity, Invus, Perceptive Advisors

Description:

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder.

Total Funding Amount:

$1.9B

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2018-10-01

Founders:

Number of Employees:

251-500

Last Funding Date:

2023-10-11

IPO Status:

Delisted

© 2025 bioDAO.ai